Silver Book Fact

Aspirin use in AFib patients

Meta-analysis of a number of randomized controlled trials found that aspirin use in atrial fibrillation patients
reduced stroke risk by an average 22%.

Hart, RG, O Benavente, R McBride, and LA Pearce. Antithrombotic Therapy to Prevent Stroke in Patients with Atrial Fibrillation. Ann Intern Med. 1999; 131(7): 492-501. http://www.annals.org/content/131/7/492.1.full

Reference

Title
Antithrombotic Therapy to Prevent Stroke in Patients with Atrial Fibrillation
Publication
Ann Intern Med
Publication Date
1999
Authors
Hart, RG, O Benavente, R McBride, and LA Pearce
Volume & Issue
Volume 131, Issue 7
Pages
492-501
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
  • AFib practice guidelines reduce direct health care costs
    The use of practice guidelines in atrial fibrillation (AF) patients significantly decreased hospitalization and resource utilization—with an average decrease in 30-day total direct health care costs of around $1,400 per patient.  
  • Cost of warfarin therapy for AFib patients
    In patients with nonvalvular atrial fibrillation (AF) and one additional stroke risk factor, warfarin therapy cost $8,000 per quality-adjusted life-year (QALY) saved.  
  • Effect of optimal anticoagulation
    If 50% of atrial fibrillation patients who currently receive warfarin in routine medical care were optimally anticoagulated, 9,852 emboli would be prevented and $1.3 billion would be saved each year.  
  • Stroke rates among Afib patients
    In one year, 58,283 of the 1.265 million Medicare beneficiaries with atrial fibrillation that did not receive prophylaxis suffered a stroke. For those who did receive anti-coagulants, 38,468 suffered strokes.